Melatonin is a substance chiefly produced by the pineal gland and has a key role in the sleep-wake cycle. It also has an important antioxidant role. Exogenous melatonin has a short half-life and is available in a range of preparations. Newer analogues targeted for the recently discovered melatonin MT1 and MT2 receptors have also been developed. Exogenous melatonin is used as a resynchronisation agent in jet lag and for other sleep disturbances.
Melatonin (N-acetyl-5-methoxytryptamine) is a naturally occurring substance produced chiefly by the pineal gland but also in much smaller amounts by the gastrointestinal tract 1 , retina 2 , platelets 3 and skin 4 . It was first isolated by Lerner in 1958 from a bovine pineal gland 5 . Although it was initially described as a hormone, it is now thought to have additional nonhormonal effects 6 .
Melatonin is produced in a stepwise process. Tryptophan is taken up from the circulation and initially converted to serotonin. Two further enzymatic reactions are responsible for subsequent conversion to melatonin 7 . Serotonin-N-acetyl transferase is thought to be the rate-limiting enzyme 8 .
This article reviews the physiology and pharmacology of melatonin followed by an overview of current and potential perioperative uses. Consideration is also given to dealing with the patient already medicated with melatonin in the perioperative period.
THE PINEAL GLAND
The pineal gland is a pea-sized structure located in the midline of the brain between the two thalami lying above the third ventricle outside the blood-brain barrier. It consists of pinealocytes surrounded by connective tissue. It has a rich sympathetic nerve supply from the superior sympathetic ganglion with a parasympathetic supply from the sphenopalatine and otic ganglia. The sympathetic supply is important for regulation of melatonin production ( Figure 1 ).
Photosensitive retinal cells detect changes in ambient light and relay this to the suprachiasmatic nucleus and then the paraventricular nuclei. The paraventricular nuclei then relay to the superior sympathetic ganglion and spinal cord. In dark situations, sympathetic input from the superior sympathetic ganglion at the pineal gland leads to increased melatonin production. This is mediated by gland stimulation, increasing cAMP and then enzyme activation including serotonin-N-acetyl transferase 9 . Ambient light inhibits this process.
The consequence is a circadian rhythm of melatonin production and release from the pineal gland. Melatonin blood levels start to rise after 2200 hours, peak around 0300 hours and return to daytime levels at 0900 hours 10 . The background levels of melatonin are probably the result of gastrointestinal secretion and not under the control of the suprachiasmatic nucleus 11 . It is not stored in the pineal gland.
PHYSIOLOGICAL ROLE OF MELATONIN
Melatonin has receptor and non-receptor mediated actions. Specific melatonin G-protein coupled receptors (MT1, MT2) are distributed widely throughout the body 12, 13 . Intranuclear melatonin receptors also exist 14 . The most established role of melatonin is a receptor-mediated chronobiotic function in the sleep-wake cycle via effects on MT1 and MT2 receptors at the suprachiasmatic nucleus 15 . Other receptor-mediated effects include roles in seasonal adaptation 16 and pubertal development 17 .
Non-receptor mediated actions of melatonin are a more recent discovery and account for its potent antioxidant effects 18 . Melatonin donates electrons to free radicals 19 with the metabolites produced also being electron donors 20 . Antioxidant enzymes including superoxide dismutase are stimulated 21 but pro-oxidant enzymes are inhibited 22 . Glutathione production is stimulated 23 . Finally, mitochondrial free-radical electron escape from the electron transport chain is decreased 24 .
PHARMACOLOGY OF MELATONIN AND AVAILABLE PREPARATIONS
Melatonin undergoes extensive first pass metabolism with varying bioavailability of 10 to 56% 25 . It is a highly lipophilic substance with a consequent high volume of distribution 26 . Ninetynine percent is metabolised in the liver to 6hydroxymelatonin by CYP1A2, conjugated to form sulphates and glucuronides and then, along with the other 1% unchanged, excreted in the urine 27, 28 . The elimination half-life in humans is approximately 45 minutes but may extend to 100 minutes in patients with cirrhosis [29] [30] [31] .
Exogenous melatonin may be chemically synthesised or produced from beef pineal glands. Prolonged-release melatonin supplements have been developed to overcome its short half-life 32 and in view of the high first-pass metabolism, sublingual melatonin is also available 33 . Intravenous preparations used in trials can be prepared by dissolving melatonin in solvents including ethanol 34 .
Melatonin analogues are being increasingly developed with the discovery of G protein coupled melatonin receptors (MT1 and MT2) 12, 13 . Ramelteon, a selective MT1 and MT2 agonist, is approved by the United States Food and Drug Administration for long-term treatment of insomnia 35 . Tasimelteon, also a selective MT1 and MT2 agonist, is undergoing phase III trials for insomnia 36 and agomelatine, an MT1/MT2 agonist and 5HT2c antagonist, is being evaluated as an antidepressant/anxiolytic drug 37 . These agents are formulated for oral administration.
SIDE-EFFECTS OF EXOGENOUS MELATONIN ADMINISTRATION
Short-term administration of oral melatonin for sleep disturbance is safe. In 2006, a meta-analysis reported that the most common side-effects of melatonin used in this setting were headache, dizziness, nausea and drowsiness 38 . However these side-effects occurred at similar frequencies in placebo groups. Other reported adverse events include an association with increased seizure duration in epileptic children 39 , a deterioration of mood in depression 40, 41 and a single case of autoimmune hepatitis 42 .
Melatonin is not recommended during pregnancy or in breast-feeding mothers because of lack of data 43 .
MELATONIN DRUG INTERACTIONS
As melatonin is metabolised by CYP1A2 there is a potential for drug interactions. The new melatonin analogue ramelteon has been extensively studied with regard to interactions. Only the interaction with fluvoxamine is thought to be clinically significant. Fluvoxamine may markedly increase ramelteon plasma concentrations and coadministration is not recommended 48 .
USE OF MELATONIN OUTSIDE THE PERIOPERATIVE SETTING Jet lag
Jet lag results from a mismatch of the body's endogenous rhythms and a new light/dark cycle being imposed. It comprises features of daytime fatigue, night-time insomnia, reduced psychomotor co-ordination, decreased alertness and a reduction in cognitive skills 49 . The therapeutic use of melatonin and its analogues aims to reset the body's day/night cycle to decrease jet lag but its use is contentious. In 2002 a Cochrane review found that if air travellers crossed five time zones or more, then melatonin was effective in decreasing jet lag 50 . Doses of 0.5 to 5 mg taken at bedtime in the place of destination were found to be efficacious. The authors suggested that the subject should take the first dose on the first day of travel and continue for several days at the destination. In addition to taking melatonin, limiting exposure to light and exercise to certain hours may also have a role in resynchronisation of the circadian rhythm 51, 52 . However, a more recent meta-analysis did not find melatonin to be efficacious for jet lag 38 . Unlike the Cochrane review, this meta-analysis did not take into account decreases in daytime somnolence as well as improvements in night-time sleep. A large degree of heterogeneity in terms of size and timing of melatonin dosing also makes comparison of studies difficult.
Melatonin and other sleep disturbance disorders
Melatonin has been used for many primary and secondary sleep disorders in all age groups. Convincing evidence is, however, lacking. For primary sleep disorders, melatonin is most effective for delayed sleep phase syndrome with sleep onset being advanced 53 . For secondary sleep disorders, two reviews by the same authors indicate that melatonin is not efficacious 38, 53 . The range of sleep disorders is wide and a large degree of variability exists for melatonin dosing to induce sleep. Subjects can also respond rapidly or need longterm treatment before any improvement in sleep results 54 . The short half-life of melatonin may explain why melatonin has limited efficacy over a whole night but can decrease sleep latency.
SURGERY, ANAESTHESIA AND MELATONIN HOMEOSTASIS
Studies have investigated plasma melatonin levels in the immediate perioperative period and the following postoperative nights. One study investigated intraoperative and immediate postoperative melatonin levels in patients undergoing gynaecological surgery. Plasma melatonin levels were raised intraoperatively in groups maintained with isoflurane and propofol, but this increase was maintained for up to eight hours only in the isoflurane group with a progressive earlier decline in the propofol group 55 .
Postoperative studies have shown that melatonin levels are decreased during the first postoperative night but generally recover by the second postoperative night. This trend has been shown in cardiac surgery 56 , major abdominal surgery 57 , gynaecological surgery 58 and knee arthroscopies 59 .
The effect of surgery and the stress response, patient factors and anaesthetic factors on the balance between melatonin secretion and elimination is unclear.
Drugs other than anaesthetic agents have been investigated for their effects on melatonin production. Benzodiazepines 60 , non-steroidal antiinflammatory drugs 61 , clonidine 62 , corticosteroids 63 and beta-blockers 64 decrease plasma levels of melatonin. Opioids may increase plasma melatonin by stimulating serotonin-N-acetyl transferase 65 .
PERIOPERATIVE USES OF MELATONIN -HYPNOSIS AND ANALGESIA
Melatonin has hypnotic and analgesic effects that have been investigated for a variety of potential perioperative uses. 66 and this was similar to subjects who received midazolam (15 mg sublingual). A subsequent study (median age 27.9 years, n=84 also for gynaecological laparoscopy) examined a variety of doses of melatonin and midazolam (0.05, 0.1 or 0.2 mg/kg sublingual) and showed equivalent sedation and anxiolysis for the melatonin and midazolam groups with superiority to placebo. The melatonin groups had less psychomotor impairment compared with the midazolam groups. A dose of 0.05 mg/kg sublingually was suggested as the optimum premedicant melatonin dose to provide adequate anxiolysis and sedation with minimal psychomotor side-effects 67 .
In adult patients (median age 39.9 years, n=66) undergoing laparoscopic cholecystectomy, both melatonin premedicated (5 mg sublingual) and midazolam premedicated (15 mg sublingual) groups had decreased preoperative anxiety compared with the placebo group and there was no decrease in postoperative neuropsychological performance 68 . In another study of American Society of Anesthesiologists (ASA) I patients (mean age 33 years, n=200) having unspecified surgery, sublingual melatonin (0.2 mg/kg) decreased preoperative anxiety and increased sedation versus placebo 69 .
In paediatric surgery, the first published study 70 investigated the effects of melatonin in children (two to five years, n=105) undergoing minor general surgical procedures. It found that oral melatonin and midazolam at 0.25 and 0.5 mg/kg were equally effective at decreasing separation anxiety and anxiety associated with the introduction of an anaesthetic facemask at induction. Another study looked at anxious children (three to eight years, n=60) undergoing dental procedures with nitrous oxide used for intraoperative sedation. Two groups received oral melatonin premedication (3 mg fixed dose group and 0.5 mg/kg group), one group received placebo and one group received midazolam (0.75 mg/kg). The melatonin groups were less sedated pre-procedure than the midazolam group and had similar sedation scores to the placebo group 65 . One further trial studied children (three to seven years, n=148) having unspecified surgery. Groups of children having 0.05, 0.2 or 0.4 mg/kg melatonin had significantly higher anxiety levels compared with another group receiving 0.05 mg/kg midazolam at the time of anaesthetic mask introduction 72 . The results of these trials using melatonin as a premedicant do not at this stage indicate that melatonin reliably produces sedation and anxiolysis in children.
In elderly patients, melatonin premedication for anxiolysis has also been less encouraging. In patients over 65 years of age (n=138) having a variety of surgical operations, patients who received 10 mg melatonin orally had no significant decrease in anxiety pre-or postoperatively versus a placebo group 73 .
Other endpoints of melatonin premedication studies, both animal and human, have involved the effects of preoperative melatonin on induction of anaesthesia with both volatile agents and intravenous agents. A study on ASA I human subjects (n=200, mean age 33.2 years) showed that 0.2 mg/ kg preoperative sublingual melatonin increased propofol potency 1.7 to 1.8 times and thiopentone potency by 1.3 to 1.4 times compared with placebo 69 .
In a more recent study in young adults with an ASA rating of I/II (n=45) using propofol titrated to achieve a bispectral index (BIS) of 45, one group received no premedication and the other groups received 3 mg or 5 mg of oral melatonin. The melatonin groups required significantly lower doses of propofol 74 .
Studies using volatile agents contrast with the findings of the studies using intravenous agents. One study used sevoflurane as an induction agent in females undergoing hysteroscopies (n=71, mean age 35 years). Prior to induction with sevoflurane, one group received sublingual melatonin (9 mg) and one received placebo. No difference between BIS values measured every 30 seconds for 300 seconds was seen between the melatonin and placebo groups during induction 75 . A study in rats also showed a lack of enhancement of volatile induction in that oral melatonin pretreatment potentiated the anaesthetic effects of thiopentone and ketamine but not ether 76 .
b) Procedural sedation
This has been evaluated in both adults and children. In adult patients over the age of 60 years (n=40), melatonin 10 mg or placebo were administered orally 90 minutes before cataract surgery with topical anaesthesia. The melatonin group had significantly lower anxiety scores, pain scores and intraocular pressure measurements. The authors postulated that the decrease in intraocular pressure was a consequence of melatonin receptors in the ciliary body tissues 77 .
In a paediatric setting, small non-controlled studies have suggested that melatonin might have a role in sedation for magnetic resonance imaging scans 78, 79 and electroencephalograms 78 . A larger randomised double-blind study (n=98) evaluated melatonin as an adjunct for magnetic resonance imaging scan sedation. In addition to a standard regimen of chloral hydrate (5 to 15 kg children) or temazepam and droperidol (15 to 40 kg children), melatonin was added at 3 or 6 mg respectively. The studies reported that melatonin did not significantly change endpoints (successful scans, time to sleep or recovery times 80 ).
c) Induction of anaesthesia
There has been no study looking at melatonin as an induction agent in humans as yet. Animal studies have indicated that high dose intravenous melatonin may have a role as an induction or coinduction agent. In rats, the loss of the righting reflex was used as an endpoint of hypnosis with intravenous melatonin proving comparable to propofol and thiopentone in onset. Haemodynamic changes including hypotension were similar for equivalent ED 50 s of propofol and melatonin 81 . A subsequent study in rats showed that intravenous melatonin produced similar effects on processed electroencephalogram variables to propofol and thiopentone at equipotent doses 82 . As an induction agent, intravenous melatonin is not very potent. However, more potent melatonin analogues may have a role in future developments 83 .
The mechanism of melatonin for induction, anxiolysis and sedation seems to relate to both melatonin receptor activation and an effect on gamma-aminobutyric acid transmission 84, 85 . It has been reported that melatonin administration in rats increases central nervous system levels of gammaaminobutyric acid and flumazenil also decreases the effects of melatonin 87, 88 . A more detailed review of the mechanisms of melatonin as an anaesthetic agent is provided by Naguib, Gottumukkala and Goldstein 89 .
d) Anti-nociception
Human studies of melatonin with relation to nociception have been limited. One study examined ASA I/II patients (n=40) undergoing procedures with intravenous regional anaesthesia who were randomised to receive a premedication of 10 mg oral melatonin or placebo. The melatonin group had lower intraoperative anxiety, lower pain scores during the procedure, lower intraoperative rescue fentanyl requirements and longer times until first postoperative analgesia request 90 .
Two further studies conducted by the same investigators involved patients undergoing total abdominal hysterectomy under epidural anaesthesia with propofol sedation (epidural catheter removed immediately postoperatively). The first of these looked at ASA I/II patients (n=33, mean age 44 years) randomised to receive oral melatonin (5 mg) or placebo the night before surgery and one hour prior to the operating theatre. The treatment group reported significantly lower postoperative pain and anxiety for the first 36 hours and also had decreased morphine consumption 85 . The second study investigated ASA I/II patients (n=59), who were randomised to receive either oral melatonin (5 mg), oral clonidine (100 µg) or placebo both the night before and one hour prior to anaesthesia. The melatonin and clonidine groups had lower anxiety scores, lower pain scores and lower morphine consumption in the first 24 hours postoperatively. However, subgroup analysis indicated that the decrease in pain scores and morphine consumption was only significant in those patients with higher preoperative anxiety scores 92 .
Further human studies have indicated that melatonin decreases pain with fibromyalgia 93 and has beneficial effects with irritable bowel syndrome 94 .
In the field of acute pain, studies on mice and rats using thermal stimuli showed that melatonin has a long-lasting antinociceptive action which may be inhibited by naloxone [95] [96] [97] . Other studies have shown that melatonin decreases inflammatory pain induced by formalin 98 , carageenan 99 or glutamate 100 in rat and mice models. Recent studies in rats have reported that melatonin has a role in decreasing hyperalgesia 101, 102 and allodynia 101 when nerves are injured.
The analgesic effects of melatonin are mediated by MT1 and MT2 receptors 103 with a subsequent reduction in intracellular cAMP, and a consequent effect on potassium and calcium channels 104 . Other analgesic effects may relate to indirect increases in endogenous opioids 105 , an effect on mRNA expression to inhibit arachidonic acid release 106 and a direct free radical scavenging effect 107 .
e) Emergence delirium in children
In children (two to five years, n=105) undergoing general surgical procedures with a nitrous oxide, sevoflurane and caudal anaesthetic technique, those receiving 0.25 or 0.5 mg/kg melatonin preoperatively had a lower incidence of excitement at 10 minutes postoperatively compared with those receiving the same doses of midzalom or placebo. At two weeks postoperatively the study also showed that the melatonin group had less sleep disturbance 70 . A more recent trial investigated children (three to seven years, n=149) having non-specified surgery with a nitrous oxide, oxygen and sevoflurane induction. It compared 0.05, 0.2 and 0.4 mg/kg preoperative melatonin with 0.5 mg/kg midazolam. Despite the melatonin groups being more anxious than the midazolam group at induction, the melatonin groups had significantly less emergence delirium compared with the midazolam group 72 . Hence the roles of midazolam and melatonin as premedicants in children appear to be very different. Current studies indicate that midazolam provides superior sedation and anxiolysis preoperatively but that melatonin reduces emergence delirium.
f) Postoperative delirium in elderly patients
Melatonin may have a role in the treatment and prevention of postoperative delirium in adults. Two case reports have been published 108 . The first describes a 53-year-old male with delirium after hip fracture surgery who did not respond to benzodiazepines or antipsychotics but responded to melatonin. The second reports the use of melatonin to prevent delirium in a 78-year-old male with a previous history of postoperative delirium.
The mechanism by which melatonin might either prevent or treat postoperative delirium is uncertain. One small study investigated elderly patients undergoing laparotomy (n=29, median age 78 years). Two groups of patients with delirium emerged. One had delirium in addition to other postoperative complications such as pneumonia, cardiac failure or haemorrhagic shock and had elevated melatonin levels at 2200 hours postoperatively compared to their preoperative levels. The other group of patients had postoperative delirium without other complications and had decreased melatonin levels at 2200 hours postoperatively compared with preoperative levels 109 . Other studies have investigated urinary metabolites of melatonin in delirious medical patients and found that they are raised with hypoactive delirium and lowered in hyperactive delirium 110 . Hence melatonin may only have efficacy in treating or preventing postoperative hyperactive delirium in patients without other complications. A randomised controlled trial investigating melatonin supplementation for treating hyperactive delirium in medical patients over 65 years old is due to be completed in 2012 111 .
ANTIOXIDANT ROLES OF MELATONIN
In view of the known antioxidant properties of melatonin, it has increasingly been investigated for practical uses relating to this action.
a) Sepsis
Multiple studies have shown benefit in animal sepsis models. Melatonin has been found to decrease lipopolysaccharide-induced lipid peroxidation in both the liver 112, 113 and lungs 113 of rats and also lower nitric oxide levels 113, 114 . In addition to these biochemical effects, reduced mortality for endotoxaemic rats has been reported with melatonin treatment 113, 115 . Beneficial effects in sepsis result from decreased cytokine release 116 , decreased leukocyte recruitment 112 , free radical scavenging 117 and decreased mitochondrial damage by both an antioxidant effect 112 and restoration of ATP production 119 .
Only one human study has as yet been undertaken. In this study on neonates with sepsis (n=20), one group received two doses of oral melatonin one hour apart (10 mg orally) within the first 12 hours of sepsis diagnosis and the other group received placebo. The melatonin group showed decreased C-reactive protein levels, white cell counts and lower levels of lipid peroxidation products but there was no significant improvement in mortality 120 .
b) Ischaemia/reperfusion injuries Central nervous system
Rat studies have shown decreased secondary injury and earlier recovery after early melatonin administration in experimental spinal cord injury 121 . Rabbit studies have also shown a benefit of decreased spinal cord injury when melatonin has been administered before or early after aortic occlusion 122 . In contrast to these positive results, a recent trial on rats with experimental spinal cord contusion did not show that administration of melatonin before or after injury improved motor function 123 .
Evidence in animals with traumatic brain injury also suggests a potential role of melatonin as a neuroprotective agent 124 . Similarly, melatonin may have a role in acute stroke treatment 125 and human trials are required to address this.
Cardiovascular system
In animal studies examining reperfusion injuries, animals treated with melatonin had lower levels of biochemical markers indicating ischaemia 126, 127 and a decrease in post reperfusion arrythmias 128 . Administration prior to ischaemia or reperfusion seems to be of greater benefit compared with later administration 127 .
Renal, hepatic and gastrointestinal systems
Reperfusion injuries of the kidney, liver and bowel have also been studied in animals with preischaemic doses of melatonin associated with preservation of organ function as determined by both biochemical markers and histological review [129] [130] [131] [132] . As a result, melatonin may in the future have a role in transplant surgery 133 .
The mechanism of protection for these reperfusion injuries is likely the result of several antioxidant effects already discussed 126, 127, 130, 132 .
MELATONIN IN INTENSIVE CARE
While many trials have looked at the role of melatonin in sleep improvement 134 , there have only been limited studies looking at melatonin with regard to sleep disturbance in intensive care. As methodologies have varied considerably and the studies have been small, it is difficult to draw conclusions. One study of only eight medical intensive care patients with respiratory failure showed that 3 mg of melatonin (at 2200 hours) improved duration and quality of sleep 135 . Another study of 32 tracheostomised intensive care patients did not show that 3 mg melatonin (at 1800 hours) improved sleep 136 . Finally the most recent study utilised BIS to measure both hours of sleep and quality of sleep in 24 tracheostomised intensive care unit patients. A dose of 10 mg oral melatonin (at 2100 hours) did not significantly increase hours of sleep but did decrease the area under the BIS curve which may indicate better sleep quality 137 . The lack of a convincing role of melatonin in intensive care sleep improvement is in keeping with the findings of research into other areas of sleep disturbance treatment with melatonin described earlier.
THE SURGICAL PATIENT ALREADY TAKING MELATONIN
In view of the potential benefits of perioperative melatonin, it would appear sensible to continue its administration if possible during the perioperative period. It must be borne in mind that patients who have recently taken melatonin may require decreased doses of intravenous induction drugs 57 . Consideration must also be given to the variety of melatonin supplements and tablets available and that the stated strength may differ from the actual strength.
CONCLUSION
Melatonin has many potential uses in the perioperative setting related to its diverse receptorand non-receptor-mediated pharmacological actions.
Despite its low cost and apparent lack of sideeffects, perioperative studies investigating melatonin are lacking.
The greatest bulk of perioperative research currently relates to receptor-mediated actions.
Although the degree of preoperative anxiolysis provided by melatonin may not prove to be equivalent to that of midazolam, especially at the extremes of age, melatonin is useful in decreasing emergence delirium. Whether a body of evidence in animal models for the use of melatonin as an analgesic can be translated into human studies will hopefully be clarified over the coming years.
Use of the antioxidant properties of melatonin in a perioperative setting lies some way off. Promising animal model research needs to be replicated in human studies.
The introduction of the new melatonin analogues such as ramelteon, tasimelteon and agomelatine will substantially increase the volume of research in due course.
